ALLK Stock Price, Allakos Inc Quote, Chart

Market Summary

USD1.21+0.01

Market Closed

0.83%

ALLK Stock Price

View Fullscreen

ALLK RSI Chart

ALLK Valuation

Market Cap

107.1M

Price/Earnings (Trailing)

-0.5

EV/EBITDA

-0.88

Price/Free Cashflow

-0.9

MarketCap/EBT

-1.35

ALLK Price/Sales (Trailing)

ALLK Profitability

Return on Equity

-206.18%

Return on Assets

-120.92%

Free Cashflow Yield

-111.29%

ALLK Fundamentals

ALLK Earnings

Earnings (TTM)

-214.4M

Earnings Growth (Yr)

-67.67%

Earnings Growth (Qtr)

-13.67%

Breaking Down ALLK Revenue

Last 7 days

3.4%

Last 30 days

9.0%

Last 90 days

-4.7%

Trailing 12 Months

-73.3%

How does ALLK drawdown profile look like?

ALLK Financial Health

Current Ratio

4.11

ALLK Investor Care

Shares Dilution (1Y)

2.29%

Diluted EPS (TTM)

-2.46

Tracking the Latest Insider Buys and Sells of Allakos Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 06, 2024	radford harlan baird	sold (taxes)	-43,391	1.35	-32,142	chief financial officer
Mar 05, 2024	tomasi adam	sold (taxes)	-68,244	1.44	-47,392	president
Mar 04, 2024	alexander robert	sold (taxes)	-104,947	1.48	-70,910	chief executive officer
Dec 04, 2023	paterson craig a.	sold (taxes)	-17,480	2.5	-6,992	chief medical officer
Dec 04, 2023	tomasi adam	sold (taxes)	-40,135	2.5	-16,054	president
Dec 04, 2023	radford harlan baird	sold (taxes)	-20,950	2.5	-8,380	chief financial officer
Dec 04, 2023	alexander robert	sold (taxes)	-61,882	2.5	-24,753	chief executive officer
Sep 05, 2023	tomasi adam	sold (taxes)	-54,839	3.01	-18,219	president
Sep 05, 2023	radford harlan baird	sold (taxes)	-28,628	3.01	-9,511	chief financial officer
Sep 05, 2023	alexander robert	sold (taxes)	-84,569	3.01	-28,096	chief executive officer

Which funds bought or sold ALLK recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	CITIGROUP INC	added	941	274,299	346,349	-%
May 10, 2024	GROUP ONE TRADING, L.P.	reduced	-73.76	-85,354	11,760	-%
May 10, 2024	JPMORGAN CHASE & CO	added	321	123,167	253,502	-%
May 10, 2024	ACADIAN ASSET MANAGEMENT LLC	added	1,753	1,482,000	1,677,000	0.01%
May 10, 2024	DIMENSIONAL FUND ADVISORS LP	reduced	-47.1	-499,254	161,270	-%
May 10, 2024	Vontobel Holding Ltd.	sold off	-100	-2,054,000	-	-%
May 10, 2024	PNC FINANCIAL SERVICES GROUP, INC.	sold off	-100	-349	-	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	15.47	-26,878	30,670	-%
May 10, 2024	VANGUARD GROUP INC	added	16.56	-4,106,540	4,781,360	-%
May 10, 2024	BlackRock Inc.	reduced	-7.73	-8,018,750	5,948,170	-%

Are Funds Buying or Selling ALLK?

Are funds buying ALLK calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ALLK

No. of Funds

Unveiling Allakos Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	deep track capital, lp	2.87%	2,510,736	SC 13G/A
Feb 14, 2024	logos global management lp	3.3%	2,900,000	SC 13G/A
Feb 14, 2024	citadel advisors llc	3.4%	6	SC 13G/A
Feb 12, 2024	price t rowe associates inc /md/	9.1%	7,920,708	SC 13G
Feb 12, 2024	price t rowe associates inc /md/	0.7%	638,102	SC 13G/A
Feb 02, 2024	rivervest venture fund iii, l.p.	0.0%	0	SC 13D/A
Jan 29, 2024	blackrock inc.	5.8%	5,116,088	SC 13G
Jan 26, 2024	deep track capital, lp	5.72%	5e+06	SC 13G
Jan 26, 2024	deep track capital, lp	2.87%	2,510,736	SC 13G/A
Jan 18, 2024	biotechnology value fund l p	5.2%	4,558,983	SC 13G/A

Recent SEC filings of Allakos Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
Apr 23, 2024	8-K	Current Report
Apr 23, 2024	ARS	ARS
Apr 23, 2024	DEF 14A	DEF 14A
Mar 19, 2024	144	Notice of Insider Sale Intent
Mar 14, 2024	10-K	Annual Report
Mar 14, 2024	8-K	Current Report
Mar 07, 2024	4	Insider Trading
Mar 06, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Allakos Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	19.54%	-2.80%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	206.31%	55.15%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	5.07%	336.18%	-13.59	481.06	-77.61%	33.36%
INO	294.6M	4.9M	3.08%	29.79%	-2.36	60.54	-54.97%	48.23%
IBIO	15.6M	2.1M	-10.40%	79.21%	-0.67	7.61	-13.45%	69.54%

Allakos Inc News

Latest updates

Allakos Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-27.2%	177	244	283	319	350	386	419	307	346	535	621	655	684	720	441	474	500	517	535	170	185
Current Assets	-17.9%	148	180	218	252	283	309	339	222	258	452	531	576	629	669	425	458	484	500	520	154	169
Cash Equivalents	-33.0%	45.00	66.00	71.00	67.00	94.00	87.00	205	82.00	36.00	155	274	204	170	207	104	154	136	41.00	309	36.00	31.00
Net PPE	-48.0%	17.00	33.00	35.00	36.00	38.00	39.00	40.00	41.00	44.00	43.00	40.00	25.00	14.00	8.00	7.00	8.00	8.00	8.00	8.00	9.00	9.00
Liabilities	-2.0%	73.00	75.00	62.00	64.00	70.00	76.00	74.00	84.00	86.00	89.00	97.00	84.00	68.00	65.00	27.00	27.00	22.00	21.00	21.00	18.00	17.00
Current Liabilities	-1.8%	36.00	37.00	23.00	24.00	30.00	30.00	28.00	37.00	38.00	40.00	41.00	34.00	23.00	22.00	19.00	20.00	14.00	13.00	12.00	9.00	8.00
Shareholder's Equity	-38.4%	104	169	221	255	280	310	344	223	260	445	525	571	616	654	414	447	478	496	514	152	168
Retained Earnings	-6.4%	-1,189	-1,118	-1,055	-1,010	-975	-932	-889	-859	-809	-612	-518	-455	-398	-342	-298	-256	-217	-189	-164	-143	-124
Additional Paid-In Capital	0.5%	1,293	1,287	1,277	1,265	1,256	1,243	1,234	1,082	1,070	1,058	1,043	1,027	1,014	997	712	703	693	685	679	295	292
Shares Outstanding	0.9%	89.00	88.00	87.00	87.00	87.00	85.00	56.00	55.00	55.00	55.00	54.00	54.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	288	-	-	-	121	-	-	-	3,237	-	-	-	2,156	-	-	-	959	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-34.0%	-32,541	-24,288	-29,479	-32,594	-30,139	-46,786	-26,128	-32,770	-174,287	-65,377	-46,435	-49,782	-46,259	-34,415	-35,823	-25,072	-18,614	-19,111	-16,199	-14,423	-13,279
Share Based Compensation	-39.1%	6,210	10,203	10,534	9,821	10,665	9,273	10,732	11,761	11,392	14,595	12,496	11,397	12,354	10,206	7,989	7,762	7,489	5,865	3,960	3,105	2,834
Cashflow From Investing	-55.3%	9,029	20,189	31,547	6,121	35,318	-71,477	7,687	78,059	57,412	-57,085	113,086	82,949	4,288	-137,525	-15,298	41,320	115,400	-249,862	-91,507	19,278	10,120
Cashflow From Financing	-	132	-	1,070	-	1,458	190	141,279	66.00	347	864	3,813	800	4,783	274,814	1,526	1,708	789	8.00	380,054	138	963

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ALLK Income Statement

2024-03-31

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses
Research and development	$ 34,824	$ 33,078
General and administrative	10,898	11,968
Impairment of long-lived assets	27,347	0
Total operating expenses	73,069	45,046
Loss from operations	(73,069)	(45,046)
Interest income	1,995	2,678
Other expense, net	(72)	(36)
Net loss	(71,146)	(42,404)
Unrealized gain (loss) on investments	(30)	296
Comprehensive loss	$ (71,176)	$ (42,108)
Net loss per common share:
Net loss per common share, basic	$ (0.81)	$ (0.49)
Net loss per common share, diluted	$ (0.81)	$ (0.49)
Weighted-average number of common shares outstanding:
Weighted-average shares of common stock outstanding, basic	88,042	85,845
Weighted-average shares of common stock outstanding, diluted	88,042	85,845

ALLK Balance Sheet

2024-03-31

BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 43,060	$ 66,440
Investments	96,192	104,354
Prepaid expenses and other current assets	8,382	9,095
Total current assets	147,634	179,889
Property and equipment, net	17,364	33,369
Operating lease right-of-use assets	10,577	24,136
Other long-term assets	1,737	6,216
Total assets	177,312	243,610
Current liabilities:
Accounts payable	15,748	1,764
Accrued expenses and other current liabilities	20,173	34,814
Total current liabilities	35,921	36,578
Operating lease liabilities, net of current portion	37,408	38,215
Total liabilities	73,329	74,793
Contingencies (Note 8)
Stockholders’ equity:
Preferred stock, $0.001 par value per share; 20,000 shares authorized as of March 31, 2024 and December 31, 2023; no shares issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.001 par value per share; 200,000 shares authorized as of March 31, 2024 and December 31, 2023; 88,544 and 87,750 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	89	88
Additional paid-in capital	1,293,497	1,287,156
Accumulated other comprehensive gain (loss)	20	50
Accumulated deficit	(1,189,623)	(1,118,477)
Total stockholders’ equity	103,983	168,817
Total liabilities and stockholders’ equity	$ 177,312	$ 243,610

About Allakos Inc

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. In addition, Allakos Inc. is conducting preclinical studies for AK007, which polarizes tumor-associated myeloid cells and promotes anti-tumor immunity. The company was incorporated in 2012 and is headquartered in San Carlos, California.

CEO	Dr. Robert Alexander Ph.D.
WEBSITE	allakos.com
INDUSTRY	Biotechnology
EMPLOYEES	123

Allakos Inc Frequently Asked Questions

What is the ticker symbol for Allakos Inc? What does ALLK stand for in stocks?

ALLK is the stock ticker symbol of Allakos Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Allakos Inc (ALLK)?

As of Mon May 13 2024, market cap of Allakos Inc is 107.14 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALLK stock?

You can check ALLK's fair value in chart for subscribers.

What is the fair value of ALLK stock?

You can check ALLK's fair value in chart for subscribers. The fair value of Allakos Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Allakos Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALLK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Allakos Inc a good stock to buy?

The fair value guage provides a quick view whether ALLK is over valued or under valued. Whether Allakos Inc is cheap or expensive depends on the assumptions which impact Allakos Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALLK.